In recent years, immune checkpoint blockade using agents such as programmed cell death protein 1 (PD-1) and programmed cell death ligand 1 (PD-L1) antibodies, which can revert effector T cell exhaustion, has become an established strategy in lung cancer treatment regimens 2. This evidence concerns the gene CD274 and lung carcinoma.